Clinical and pharmacokinetic study of parenteral administration of cefsulodin in pediatric patients in Japan.
A multicenter study of cefsulodin was carried out with pediatric patients having infections caused by Pseudomonas aeruginosa. Clinical responses were evaluated in 78 of 84 cases, and bacteriologic responses were evaluated in 77 cases. Peak serum levels, urinary excretion rates, and biologic half-lives were determined for some patients. Daily dosage of cefsulodin was usually 60-100 mg/kg of body weight given in three to four divided doses. Infections were mainly septicemia (12 cases), respiratory tract infections (23), and urinary tract infections (26); clinical responses in these cases were excellent or good in 75.0% of the cases (nine of 12), 78.3% (18 of 23), and 84.6% (22 of 26), respectively. P. aeruginosa was eradicated in 67.5% of patients (52 of 77) and was replaced in an additional 5.2% (four of 77). No adverse reactions were observed except for four cases of eosinophilia and one case in which serum transaminase levels were elevated. These results indicate that cefsulodin is a safe and useful drug for the treatment of pseudomonal infections in pediatric patients.
D000293:Adolescent; D002441:Cefsulodin / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006207:Half-Life; D006801:Humans; D007223:Infant; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D007564:Japan; D007700:Kinetics; D008297:Male; D011552:Pseudomonas Infections / Q000188:drug therapy*
D002441:Cefsulodin